

1637



PATENT  
Customer No. 22,852  
Attorney Docket No. 3495.0010-20

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
 )  
Marc ALIZON et al. ) Group Art Unit: 1637  
 )  
Application No.: 08/308,219 ) Examiner: Jeffrey Norman Fredman  
 )  
Filed: September 19, 1994 )  
 )  
For: DNA SEQUENCE OF THE LTR REGION OF HUMAN  
IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) (as amended)

**Mail Stop Non-Fee Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**TRANSMITTAL LETTER**

Applicants submit the following paper. The items checked below are appropriate:

☒ A Supplemental Amendment is enclosed. The claims are calculated as follows:

	Claims Remaining After Amendment		Highest Number Previously Paid	Present Extra	Rate	Additional Fee
Total	9	-	20	0	x \$ 18	\$ -0-
Indep.	1	-	3	0	x \$ 84	-0-
<input type="checkbox"/> First Presentation of Multiple Dep. Claim(s)					+\$280	-0-
Subtotal						\$ -0-
Reduction by 1/2 if small entity						- -0-
TOTAL						\$ -0-

☒ No additional claims fee is due.


Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: March 2, 2004

By: \_\_\_\_\_



Salvatore J. Arrigo

Registration No. 46,063

Telephone: 202-408-4160

Facsimile: 202-408-4400

E-mail: arrigos@finnegan.com



PATENT  
Customer No. 22,852  
Attorney Docket No. 3495.0010-20

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: )  
)  
Marc ALIZON et al. ) Group Art Unit: 1637  
)  
Application No.: 08/308,219 ) Examiner: Jeffrey Norman Fredman  
)  
Filed: September 19, 1994 )  
)  
For: DNA SEQUENCE OF THE LTR REGION OF HUMAN IMMUNODEFICIENCY  
VIRUS TYPE 1 (HIV-1) (as amended)

**Mail Stop Non-Fee Amendment**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**SUPPLEMENTAL AMENDMENT**

Applicants request that the following supplemental amendments and remarks be entered and considered by the Examiner. Please amend this application as follows.

**Amendments to the Claims** are reflected in the listing of claims in this paper.

**Remarks** begin on page 5 of this paper.